Obama’s SOTU address highlights ACA, new individualized medicine initiative

Laura Pedulli | | Health Exec | Policy & Regulations

 

In his State of the Union address, President Barack Obama described the Affordable Care Act as part of the fabric of middle-class economic recovery as he spoke to a Republican-controlled Congress still working to dismantle the law, reports Clinical Innovation + Technology.

"We can't put the security of families at risk by taking away their health insurance, or unraveling the new rules on Wall Street, or refighting past battles on immigration when we've got a system to fix," Obama said. "And if a bill comes to my desk that tries to do any of these things, it will earn my veto."

Obama also proposed the Precision Medicine Initiative to fight diseases such as cancer and diabetes. "I want the country that eliminated polio and mapped the human genome to deliver a new era of medicine, one that delivers the right treatment at the right time."

Read more below:

Healthcare an important topic in Obama's SOTU address

Laura Pedulli

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.